A multicenter, phase II trial of triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for highly emetogenic chemotherapy in breast cancer (PATROL-II)
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
No abstract available